Cliff Asness's SLNO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 58,752 shares of Soleno Therapeutics, Inc. (SLNO) worth $2.72 M, representing 0.00% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in SLNO, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 33,441 shares. Largest reduction occurred in Q1 2025, reducing 7,635 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Soleno Therapeutics (SLNO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Soleno Therapeutics (SLNO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +21,655 | Add 58.37% | 58,752 | $46.30 |
| Q3 2025 | +33,441 | Add 914.69% | 37,097 | $67.60 |
| Q2 2025 | +543 | Add 17.44% | 3,656 | $83.78 |
| Q1 2025 | -7,635 | Reduce 71.04% | 3,113 | $71.45 |
| Q4 2024 | -1,530 | Reduce 12.46% | 10,748 | $44.95 |
| Q3 2024 | +12,278 | New Buy | 12,278 | $50.49 |
| Q2 2024 | -6,792 | Sold Out | 0 | $0.00 |
| Q1 2024 | +6,792 | New Buy | 6,792 | $42.80 |
| Q1 2021 | -3,929 | Sold Out | 0 | $0.00 |
| Q4 2020 | -2,976 | Reduce 43.10% | 3,929 | $29.02 |
| Q3 2020 | +6,905 | New Buy | 6,905 | $37.65 |
Cliff Asness's Soleno Therapeutics Investment FAQs
Cliff Asness first purchased Soleno Therapeutics, Inc. (SLNO) in Q3 2020, acquiring 6,905 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Soleno Therapeutics, Inc. (SLNO) for 11 quarters since Q3 2020.
Cliff Asness's largest addition to Soleno Therapeutics, Inc. (SLNO) was in Q3 2025, adding 37,097 shares worth $2.51 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 58,752 shares of Soleno Therapeutics, Inc. (SLNO), valued at approximately $2.72 M.
As of the Q4 2025 filing, Soleno Therapeutics, Inc. (SLNO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Soleno Therapeutics, Inc. (SLNO) was 58,752 shares, as reported at the end of Q4 2025.